HDAC9 and ovarian carcinoma: Currently, there are more than a dozen of HDAC inhibitors in various stages of clinical development, mostly in phase I/II clinical trials for a variety of cancers, including valproate, which is in phase III trials for cervical cancer and ovarian cancer [118].